Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | RNF168 | Q8IYW5 | 1/20 | 0.46 |
| ▸ | CD22 | P20273 | 1/20 | 0.44 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LY6K | Q17RY6 | 1/20 | 0.43 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | PDE6D | O43924 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974776 | 0.95 | PKM (0.49) | PKMOPRM1GBA1RNF168CD22 | |
| SCHEMBL24974600 | 0.91 | GBA1 (0.50) | PKMOPRM1GBA1RNF168CD22 | |
| SCHEMBL24974781 | 0.91 | SIRT2 (0.48) | PKMOPRM1GBA1RNF168CD22 | |
| SCHEMBL24974743 | 0.91 | OPRM1 (0.48) | PKMOPRM1GBA1RNF168CD22 | |
| SCHEMBL24974540 | 0.90 | PKM (0.47) | PKMOPRM1RNF168CD22SENP1 | |
| SCHEMBL24974638 | 0.90 | PKM (0.47) | PKMOPRM1GBA1CD22SENP1 | |
| SCHEMBL19006139 | 0.79 | OPRM1 (0.57) | PKMOPRM1GBA1CD22SENP1 | |
| SCHEMBL24974368 | 0.78 | PKM (0.47) | PKMOPRM1GBA1LY6KF2 | |
| SCHEMBL24974634 | 0.77 | POLB (0.56) | POLB | |
| SCHEMBL24974545 | 0.76 | PKM (0.46) | PKMOPRM1GBA1LY6KF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | PKM 3656/4885OPRM1 614/4885GBA1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.